U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB or

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many she	els as i	recessa	(נכי	
1	<u> </u>			

	Complete if Known	
Application Number	10/677,856	
Filing Date	October 2, 2003	
First Named Inventor	Groot et al.	
Group Art Unit	To be assigned	
Examiner Name	To be assigned	<del></del>
Attomey Docket Number	2183-6143115	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
SL		PCT International Preliminary Examination Report, PCT/NL01/00610, dated July 23, 2002, 2 pages.	/
	卜		

Examiner Signature	/Sue Liu/	Date Considered	05/24/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE Application Number To be assigned October 2, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor Groot et al. Group Art Unit To be assigned (use as many sheets as necessary) To be assigned Examiner Name 2183-6143US of 2 Sheet Attorney Docket Number

	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevan
aminer Cite	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
SL	US-US 2002/0034726 A1	03-21-2002	Kanegasaki et al.	
	US-			/
	US-			
$A \perp I$	US-			
	US-			
_\	US-			
$\longrightarrow$	US-			
Y	US-			
	US-			
$-\!\!\!/\!$	US-			
	US-			
/ / \ _	US-			
/ \_	US-			
/	US-			
$\longrightarrow$	US-	ļ		

Examiner	Cite		Foreign Patent Document	]	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т°
SL	1	/	WO 99/37809	07-29-1999	Axys Pharmaceuticals, Inc.		
		7	WO 99/62556	12-9-1999	Effector Cell Institute		
17			WO 02/14366 A2	02-21-2002	Universiteit Utrecht		
$-\Lambda$	7		EP 1 182 255 A1	08-16-2000	Universiteit Utrecht		
<del>-</del>							
	7						

Examiner Signature /Sue Liu/ Date Considered 05/24/2006			
	· ·	/Sue Liu/	05/24/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/	Substitute for form 1449A/PTO			Complete if Known
INFORMATION DISCLOSURE		Application Number	To be assigned	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Filing Date	October 2, 2003	
		First Named Inventor	Grout et al.	
		Group Art Unit	To be assigned	
		Examiner Name	To be assigned	
Sheet 2	Of	2	Attorney Docket Number	2183-6143115

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т	2
SL	1/	KIKLY et al., Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils, Journal of Allergy and Clinical Immunology, June 2000, pp. 1093-1100, Vol. 105, No. 6, Part 1.	1	
1	V	LURTON et al., Isolation of a Gene Product Expressed by a Subpopulation of Human Lung Fibroblasts by Differential Display, Am. J. Respir. Cell Mol. Biol., February 1999, pp. 327-31, Vol. 20, No. 2.		
	X	WELFORD et al., Detection of differentially expressed genes in primary tumor tissues using representational differences analysis coupled to microarray hybridization, Nucleic Acids Research, 1998, pp. 3059-65, Vol. 26, No. 12.		
V	M	PCT International Search Report, PCT/NL01/00610, dated April 15, 2002.		
1	/			
$\bigvee$				
$\wedge$				
$\mathcal{T}$				
7				
			1	
Examiner Signature		/Sue Liu/ Date 05/24/20	06	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>1</sup> Unique citation designation number (optional). 1 Applicant is to place a check mark here if English language Translation is attached.